Metabolic Effects of Direct-Acting Antiviral Therapy in Chronic Hepatitis C: A Focus on Glucose and Lipid Profiles

Metabolic Effects of Direct-Acting Antiviral Therapy in Chronic Hepatitis C: A Focus on Glucose and Lipid Profiles | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Metabolic Effects of Direct-Acting Antiviral Therapy in Chronic Hepatitis C: A Focus on Glucose and Lipid Profiles Haythem Yacoub, Salma Merhaben, Dhouha Cherif, Habiba Debbabi, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7377090/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Hepatitis C virus (HCV) infection is a leading global cause of chronic liver disease and is increasingly recognized for its extrahepatic metabolic consequences, particularly in lipid and glucose homeostasis. The introduction of direct-acting antiviral agents (DAAs) has revolutionized HCV therapy, enabling high sustained virological response (SVR) rates. However, the metabolic impact of viral eradication remains incompletely understood. This study aimed to evaluate changes in fasting lipid and glycemic parameters following successful DAA therapy. A single-center, retrospective observational study was conducted at La Rabta Hospital (Tunis), including 49 consecutive patients with chronic hepatitis C who received DAA therapy between 2016 and 2022 and achieved SVR at both 12 and 48 weeks post-treatment. Patients with confounding metabolic or hepatic comorbidities were excluded. Fasting glucose, total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol levels were compared before and after antiviral therapy. Post-treatment, a statistically significant reduction in mean fasting glucose was observed (6.1 ± 2.1 to 5.8 ± 1.9 mmol/L; p = 0.048), alongside a significant increase in total cholesterol (3.8 ± 0.8 to 4.1 ± 0.9 mmol/L; p = 0.015). Changes in triglycerides, HDL-C, and LDL-C were not statistically significant. These findings suggest that HCV eradication via DAA therapy may improve glycemic control and an increase total cholesterol. Routine metabolic surveillance post-SVR is advisable, particularly in patients with elevated cardiovascular risk. Further prospective studies are warranted to elucidate the long-term clinical implications. Introduction Hepatitis C virus (HCV) infection remains a significant global public health challenge, affecting approximately 3% of the world’s population according to the World Health Organization (WHO)(1). Chronic hepatitis C (CHC) is not only a leading cause of severe hepatic complications, including cirrhosis and hepatocellular carcinoma, but is also increasingly recognized for its association with systemic metabolic disturbances. These include insulin resistance, type 2 diabetes mellitus, and dyslipidemia, all of which contribute to an elevated risk of cardiovascular disease and complicate the clinical management of affected individuals. Interestingly, HCV infection is paradoxically associated with reduced levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, resulting in a distinctive lipid profile whose underlying mechanisms and clinical implications remain incompletely understood. The advent of second-generation direct-acting antiviral agents (DAAs) has revolutionized the treatment of CHC, offering high rates of sustained virological response (SVR) with minimal side effects. While the primary goal of DAA therapy is to halt liver disease progression and reduce the risk of complications, growing evidence suggests that viral clearance may also influence metabolic parameters, including lipid and glycemic profiles. However, the impact of HCV eradication on lipid and glycemic metabolism remains controversial, with studies reporting conflicting results regarding changes in glucose, triglycerides, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels post-treatment. This study aims to evaluate changes in lipid and glycemic profiles before and after DAA treatment, focusing on the impact of viral eradication on glucose, triglyceride, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels. By addressing these questions, this research seeks to contribute to a more comprehensive understanding of the systemic effects of HCV infection and its treatment, ultimately improving patient care and outcomes. Patients and data collection We performed a single-center, retrospective, observational study with longitudinal follow-up, conducted in the gastroenterology department at La Rabta Hospital in Tunis. We included all consecutive patients hospitalized between January 2016 and December 2022. Inclusion criteria wereall patients aged 18 years or older with chronic hepatitis C who were followed during the specified period, were DAA-naïve, received DAA therapy, and achieved SVR at both 12 and 48 weeks after the end of treatment. Exclusion criteria were: Patients withdecompensatedcirrhosis. Hepatocellular carcinoma (HCC) at the time of diagnosis or during the 12 months following treatment. Co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV). Liver transplant recipients. Use of lipid-lowering therapy. Familial forms of dyslipidemia. Pregnancy Incompletemedical records. Clinical and demographic data were collected from patients' electronicmedical records. A detailed form was completed, and the variables analyzed included: age, sex, lifestyle habits, and medical history. Biological parameters before the initiation of DAA therapy and after HCV eradication were recorded. For each patient, the degree of fibrosis before starting antiviral treatment was assessed. Treatment Regimen All patients were treated in accordance with the guidelines established by the European Association for the Study of the Liver (EASL) panel. The following treatment regimens were administered: sofosbuvir (SOF) combined with ribavirin (RBV) (SOF/RBV), and sofosbuvir (SOF) combined with ledipasvir (SOF/LDV). Serum HCV RNA levels were measured at multiple time points: before the initiation of therapy and at 12 and 48 weeks after the end of therapy. Sustained virological response was defined as undetectable HCV RNA 12 weeks after the completion of treatment. Statistical Analysis All the Statistical analysis were carried through Statisti-cal Package for the Social Sciences (SPSS) version 22,0 IBM SPSS Inc.; Chicago, IL, USA).Categorical variables were summarized as frequencies and percentages. Continuous variables were expressed as means with standard deviation (SD) or medians with interquartile range (IQR), depending on the distribution of the data. Group comparisons were performed using the t-test for normally distributed data or the Mann-Whitney test for non-normally distributed continuous variables, as appropriate. We then investigated the factors associated with changes in fasting blood glucose and lipid-related markers following HCV therapy with direct-acting antivirals (DAAs). A 10% variation threshold was applied uniformly across all parameters. Based on this threshold, two groups were compared: one exhibiting a >10% variation and one without significant variation. A p-value < 0.05 and a 95% CI not including 1 were considered statistically significant for all analyses. Results Baseline Characteristics During the study period, 74 patients were initially screened for inclusion in the study. All of them initiated direct-acting antiviral (DAA) treatment. Of these, 49 patients (4 males and 45 females)met the inclusion criteria and were included in the final analysis.The mean age was 60.8±11.8 years. Twenty-five (51%) had a history of hypertension, and five (10%) were diabetic, including two (4%) requiring insulin therapy. Only one patient (2%) had hypertriglyceridemia managed with dietary modifications. Hepatic risk factors were identified in 36 out of 49 patients (73%), including prior blood transfusion (10 patients, 20%), dental procedures (25 patients, 51%), tattoos (7 patients, 14%), scarifications (22 patients, 45%), and intravenous drug use (2 patients, 4%). The baseline demographics, clinical and biological characteristics of patients are summarized in Tables 1 and 2. No patients tested positive for HBs antigen. Five patients (10%) had positive anti-HBc antibodies with negative HBV PCR, and all of them had protective levels of anti-HBs antibodies (>10 IU/mL). HIV serology was negative in all cases. Genotype 1b was the most prevalent, accounting for 81.6% of cases.Themean virological load was of 3077971,3 UI/L. Liver fibrosis assessment was performed using liver biopsy in 12 patients (24%), primarily for etiological diagnostic clarification. The remaining patients underwent non-invasive fibrosis evaluation via transient elastography (FibroScan, 12 patients, 24%) or FibroTest(25 patients, 51%). Of the 49 patients included in the study, 44 (90%) exhibited significant fibrosis (stage F2 or higher), and 35 (71%) had advanced fibrosis (stage F3 or higher). Thirteen patients (27%) exhibited endoscopic signs of portal hypertension. Cryoglobulinemia was positive in 10 patients (20%). The characteristics of viral hepatitis C infection in our patients were summarized in table 3. Among the patients, 37 (75.5%) were treatment-naïve, while 12 (24.5%) had prior treatment experience with pegylated interferon. All patients received hepatitis C virus (HCV) eradication therapy in accordance with the national Tunisian consensus guidelines in effect at the time, prior to the introduction of pangenotypic regimens. Of these, 42 patients (86%) were treated with sofosbuvir and ledipasvir, while 7 patients (14%) received a combination of sofosbuvir and ribavirin(genotype 2 and 3). Treatment duration was 12 weeks in 24 patients (49%) and 24 weeks in 25 patients (51%). Adherence to therapy was excellent in 48 out of 49 patients (98%), with good overall tolerability. Minor adverse effects were reported by 2 patients (4%): one (2%) experienced headache, and another (2%) reported asthenia. The HCV eradication rate was outstanding, with undetectable HCV PCR at both 12 and 48 weeks post-treatment in 100% of cases. Treatment outcomes were summarized in table 4. We compared fasting lipid and glucose profiles before treatment and during the first year following the completion of direct-acting antiviral (DAA) therapy. Evolution of Fasting Blood Glucose and Lipid Profile Before and After HCV Antiviral Therapy (Table 5) The mean fasting blood glucose level decreased from 6.1 mmol/L (range: 4.27–14 mmol/L; SD = 2.1) before treatment to 5.8 mmol/L (range: 4.0–13.5 mmol/L; SD = 1.86) after treatment, with a statistically significant difference ( p = 0.048 ). The mean total cholesterol level increased from 3.8 mmol/L (range: 2.16–5.58 mmol/L; SD = 0.87) to 4.1 mmol/L (range: 1.4–6.1 mmol/L; SD = 0.86), also showing a statistically significant difference ( p = 0.015 ). The mean triglyceride level showed a slight decrease from 1.26 mmol/L (range: 0.5–3.1 mmol/L; SD = 0.6) to 1.19 mmol/L (range: 0.7–3.62 mmol/L; SD = 0.64), but this change was not statistically significant ( p =0.318 ). The mean HDL-cholesterol level increased from 1.1 mmol/L (range: 0.41–1.91 mmol/L; SD = 0.34) to 1.28 mmol/L (range: 0.8–1.91 mmol/L; SD = 0.29), with no statistically significant difference observed ( p =0.345 ). Similarly, the mean LDL-cholesterol level rose slightly from 2.1 mmol/L (range: 0.49–4.06 mmol/L; SD = 0.8) to 2.28 mmol/L (range: 0.4–4.1 mmol/L; SD = 0.82), with no statistically significant change ( p =0.440 ). In the univariate analysis, a significant association was observed between the >10% variation in fasting blood glucose and a single clinical parameter: the initial viral load (p = 0.031) .However, no significant correlation was found in the multivariate analysis (table 6). No significant correlation was observed between a >10% variation in triglyceride levels and the variables studied, either in univariate or multivariate analysis. No significant correlation was observed between a>10% variation in total cholesterol levels and the variables studied, either in univariate or multivariate analysis (table 7). In the univariate analysis, a significant association was observed between the >10% variation in HDL cholesterol and only one clinical parameter: initial disturbance in liver function tests (p = 0.02). However, no significant correlation was found in the multivariate analysis. No significant correlation was observed between a >10% variation in LDL-cholesterol levels and the variables studied, either in univariate or multivariate analysis. Table 1. Baseline Demographics and Clinical Characteristics of Patients Parameter Total (n = 49) N, percentage Sex , n (%) Female Male 45(92%) 4 (8%) Male-to-Female Ratio 1:11 Mean Age (years) ,mean ( SD) 60.8(11.8) Mean Weight (kg) mean, ( SD) 70 (13.0) Mean BMI (kg/m²),mean, ( SD) 28.2 (4.9) Comorbidities - Hypertension n (%) 25(51%) - Diabetes mellitus n (%) 5(10%) - Insulin-dependent n (%) 2(4%) - Hypertriglyceridemia (diet-controlled) n (%) 1(2%) - Chronic kidney disease (hemodialysis) n (%) 1(2%) - Hypothyroidism (on replacement therapy, euthyroid) n (%) 4(8%) - Coronary artery disease n (%) 2(4%) - History of Extrahepatic Malignancies (in remission) (%) 2(4%) Smoking and alcohol Use - Smokers(%) 5(10%) - Mean Pack-Years 18 - AlcoholConsumers(%) 1 (2%) HepaticRiskFactors 36 (73%) - Prior Blood Transfusion(%) 10 (20%) - Dental Procedures(%) 25 (51%) - Tattoos(%) 7 (14%) - Scarifications(%) 22 (45%) - Intravenous Drug Use(%) 2 (4%) Table 2. Baseline Biological Characteristics of Patients BiologicalParameters Baseline (Mean ± SD) - Hemoglobin (g/dL) 12.6 ± 2 - Platelet Count (cells/mm³) 158,659 ±84913.5 - Prothrombin Time (TP, %) 82 ± 14.7 - INR 1.11 ± 0.1 - Total Bilirubin (µmol/L) 14.7 ± 9.8 - Albumin (g/L) 37.2 ± 4.4 - AST (ASAT, × ULN) 1.9 ±1.2 - ALT (ALAT, × ULN) 1.4 ±1.2 Table 3. Characteristics of viral hepatitis C infection in our patients Table 4. Treatment outcomes of viral hepatitis C in our patients Treatment-Naïve Patients(%) 37 (76%) Previously Treated with Pegylated IFN(%) 12 (25%) HCV Eradication Therapy Sofosbuvir + Ledipasvir(%) Sofosbuvir + Ribavirin(%) 42 (86%) 7 (14%) Treatment Duration 12 Weeks(%) 24 Weeks(%) 24 (49%) 25 (51%) TreatmentAdherence (%) 48 (98%) Adverse Effects (%) Headache (n, %) Asthenia (n, %) 2 (4%) 1 (2%) 1 (2%) HCV Eradication Rate (Negative PCR at 12 & 48 Weeks) (%) 49 (100%) Table 5. Changes in Fasting Blood Glucose and Lipid-Related Markers after HCV therapy with DAA Studied parameter Baseline (Mean ± SD) After treatment (Mean ± SD) P value Fasting Glucose (mmol/L) 6.1 ± 2.1 5.8 ± 1.9 0.048 Total Cholesterol (mmol/L) 3.8 ± 0.8 4.1 ± 0.9 0.015 Triglycerides (mmol/L) 1.2 ± 0.6 1.2 ± 0.6 0.318 HDL Cholesterol (mmol/L) 1.1 ± 0.3 1.3 ± 0.3 0.345 LDL Cholesterol (mmol/L) 2.1 ± 0.8 2.28 ± 0.8 0.440 Table 6. Factors Associated with Δ Fasting Blood Glucose value after HCV therapy with DAA regimen, Analyzed by Multiple Logistic-regression Analysis Studied parameter Δ FBG >10%n(%)/mean ±SD Δ FBG < 10% n(%)/mean ±SD Univariate Multivariate OR (95% CI) P-Value P-Value (n=6) (n=43) Age, year 62.1±14.1 60.5±9.9 0.790 0.274 1.095 Sex,Male(n=4) 0(0%) 4(100%) 1.000 0.999 0.000 BMI (kg/m2 ) 25.1±5.7 28.7±4.9 0.238 0.178 0.829 HCV-RNA (10 6 UI/ml) 8.7 ±1.1 34 ±37.7 0.031 0.359 1.000 AST >ULN (n=20) 3(15%) 17(85%) 0.683 0.308 12.119 ALT >ULN (n=31) 6(19%) 25 (81%) 0.649 0.279 0.181 Fibrosis >F2 (n=35) 6 29 0.309 0.999 0.957 FBG: Fasting blood glucose Table 7. Factors Associated with Δ cholesterol value after HCV therapy with DAA regimen, Analyzed by Multiple Logistic-regression Analysis Studied parameter Δcholesterol >10% n(%)/mean ± SD Δcholesterol < 10% n(%)/mean ± SD Univariate Multivariate OR (95% CI) P-Value P-Value (n= 17) (n=32) Age, year 59.2 ±11.0 61.9 ±12.1 0.451 0.692 1.015 Sex, Male (n=4) 2 2 0.602 0.379 3.516 BMI (kg/m 2 ) 28.4±5.3 28.3±5.0 0.984 0.643 1.035 HCV-RNA (10 6 IU/ml) 37.0 ± 43.0 29.1±32.9 0.529 0.260 1.000 AST > ULN (n=32) 11(34,4%) 21 (65,6%) 0.739 0.159 0.522 ALT > ULN (n=21) 6 (29%) 15(71%) 0.756 0.212 2.373 Fibrosis >F2 (n=34) 13 (38,2%) 21(61,8%) 0.739 0.305 2.576 Discussion HCV infection exerts significant metabolic effects beyond its primary hepatic manifestations and is consistently associated with alterations in lipid metabolism, including lower serum cholesterol and triglyceride levels (2-4). Several studies have also demonstrated reductions in both HDL-C and LDL-C levels (5). These changes can be partly attributed to the HCV core protein, which downregulates the expression of peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor regulating genes involved in fatty acid oxidation. Reduced hepatic levels of PPAR-α mRNA have been observed in HCV-infected patients (6,7). Additionally, the HCV core protein is thought to inhibit microsomal triglyceride transfer protein (MTP) activity, an enzyme essential for the assembly and secretion of very low-density lipoproteins (VLDL), potentially leading to impaired VLDL synthesis and triglyceride accumulation (8). Despite this seemingly favorable lipid profile, HCV infection has been associated with an increased risk of atherosclerosis and cardiovascular events (9). Indeed, patients with HCV infection have a higher risk of major cardiovascular events compared to uninfected controls, independent of liver disease severity or traditional cardiovascular risk factors (10,11). In addition to its impact on lipid profiles, HCV has also been implicated in impaired glucose metabolism, with numerous studies reporting an increased prevalence of insulin resistance (IR) and type 2 diabetes mellitus (DM) in HCV-infected individuals. These metabolic disturbances may result from direct viral interference with insulin signaling as well as indirect mechanisms involving hepatic steatosis and chronic inflammation (5). With the advent of direct-acting antiviral (DAA) agents, the long-standing goal of HCV eradication has been achieved through highly effective and well-tolerated therapies. However, questions have arisen regarding their effects on lipid and glucose metabolism. When comparing fasting lipid and glucose profiles before treatment and during the first year following the completion of direct-acting antiviral (DAA) therapy,findings across various studies may be inconsistent or even contradictory. Evolution of lipids profile: In our study, total cholesterol levels showed a significant increase after treatment, while triglyceride levels decreased slightly; however, this change was not statistically significant. Similarly, both HDL and LDL cholesterol levels exhibited modest increases, though these changes did not reach statistical significance. A meta-analysis published by Villani et al. in 2021 synthesized data from fourteen observational studies to assess the extent of serum lipid profile changes during DAA therapy (12). The findings indicated that DAA treatment induces a mild but statistically significant increase in serum cholesterol levels, regardless of the antiviral regimen used, consistent with the results of our study. This increase appears to be primarily driven by an early rise in LDL cholesterol observed shortly after treatment initiation. On average, total cholesterol levels increased by approximately 19 mg/dL at SVR12 and 20 mg/dL at SVR24. The same meta-analysis revealed a significant increase in HDL-cholesterol levels both during and after direct-acting antiviral (DAA) treatment. On treatment, HDL levels increased by an average of 2.62 to 4 mg/dL, and after treatment completion, this increase ranged from 3.17 to 4.34 mg/dL. These changes were statistically significant at multiple time points, including 4 and 8 weeks, as well as at SVR12 and SVR24. These results could be partly explained by the suggestion of Hashimoto et al., who proposed that that the rapid suppression of HCV core proteins induced by direct-acting antiviral (DAA) therapy may disrupt host lipid metabolism, leading to a reduction in lipid droplet production in HCV-infected liver cells and a significant rebound in circulating LDL levels(13). Despite these findings, heterogeneity across studies was noted, indicating variability in the response, particularly with different antiviral regimens and different virus genotypes. In fact, Doyle et al. reported that lipid changes during treatment appeared to be influenced by ribavirin exposure, suggesting a direct impact of this drug on lipid homeostasis. In particular, non-cirrhotic patients receiving ribavirin showed reductions in total cholesterol, LDL-C, and apoB levels at Weeks 4 and 12 post treatment(14). Regarding triglycerides, the pooled data from ten studies out of fourteen from the same meta-analysis showed no significant changes in triglyceride levels during or after DAA therapy. At 4 weeks, there was a minor decrease, and at SVR12, there was a small increase, but neither change reached statistical significance. This suggests that, unlike HDL-cholesterol, triglyceride levels are not notably affected by antiviral therapy, regardless of the timing after treatment or the specific antiviral regimen used(12). Evolution of glucose profile: In our study,we found a significant reduction in fasting blood glucose levels following HCV antiviral therapy. Our findings are consistent with those of a Spanish study published in 2019, in which median serum glucose levels decreased from 95 (88–105) to 94 (86–103) mg/dL (p = 0.008).(15) An Italian study conducted by Gitto et al. revealed that the mean glycemia values remained unchanged, whereas mean insulin levels and HOMA-IR significantly decreased (from 16.5 ± 7.3 to 11.6 ± 5.8, p < 0.001, and from 3.8 ± 1.9 to 2.7 ± 1.5, p < 0.001, respectively)(16). In contrast, Doule et al. reported no consistent changes in glucose homeostasis during treatment or after achieving SVR. Specifically, HOMA-IR values did not improve from baseline at any point during or following DAA therapy (14). The majority of studies suggest an improvement in glucose metabolism accompanied by worsening of the lipid profile, prompting some authorsto raise concerns regarding the overall cardiovascular balance in patients with CHC (16). Although these changes may be statistically significant, their clinical relevance in terms of cardiovascular risk remains questionable. Therefore, future research should aim to evaluate the true cardiovascular impact of these metabolic changes in high-risk CHC patients and to determine any potential clinical benefits. This study has several limitations. First, the relatively small number of patients included. Second, the retrospective design inherently carries potential biases. Additionally, we were unable to collect detailed information on behavioral factors known to influence the natural history of CHC, such as alcohol consumption, dietary habits, and physical activity. Finally, body weight and body mass index (BMI) were not recorded after virus clearance, limiting our ability to assess potential metabolic changes post-treatment. Conclusion This study highlights the systemic impact of HCV beyond liver disease, particularly its influence on metabolic parameters. Following successful treatment with DAAs, we observed a significant decrease in fasting blood glucose levels and an increase in total cholesterol. Although changes in HDL, LDL, and triglycerides were not statistically significant, the trends align with previous studies suggesting a metabolic shift post-HCV eradication. These findings reinforce the importance of monitoring metabolic parameters after viral clearance, especially in patients with cardiovascular risk factors. Further prospective studies with larger cohorts are needed to better understand the long-term clinical implications of these changes. Declarations Declarations Ethics approval and consent to participate This study was performed according to the Declaration of Helsinki, following the guidelines for good clinical practice. “La Rabtahospital ethics committee” approved the study protocol. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent to participate in the study was obtained from participants. Consent for publication: Not applicable. Competing interests : The authors declare no competing interests. Author contributions: H.Y: concept, design, definition of intellectual content, literature search, manuscript preparation, manuscript editing, manuscript review. S.M: concept, design, definition of intellectual content, manuscript preparation, manuscript review. D.C: Definition of intellectual content, manuscript preparation, design, manuscript review. H.D: Definition of intellectual content, design. H.H: Definition of intellectual content, manuscript preparation. H.K: Definition of intellectual content, manuscript preparation. N.M: Definition of intellectual References MohdHanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–42. https://doi.org/10.1002/hep.26141 Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997;261:159–65. https://doi.org/10.1016/S0009-8981(97)06483-8 Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006;13:56–61. https://doi.org/10.1111/j.1365-2893.2005.00650.x Marzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007;56:1105–10. https://doi.org/10.1136/gut.2006.099630 Dai C, Yeh M, Huang C, Hou C, Hsieh M, Huang J, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2015;30:879–84. https://doi.org/10.1111/jgh.12856 De Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-α and -γ mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006;23:107–14. https://doi.org/10.1111/j.1365-2036.2006.02738.x Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, et al. Impaired expression of the peroxisome proliferator–activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005;128:334–42. https://doi.org/10.1053/j.gastro.2004.11.004 Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185–94. https://doi.org/10.1096/fj.01-0468com Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol 2015;7:2214–9. https://doi.org/10.4254/wjh.v7.i19.2214 Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 2016;150:145–55.e4. https://doi.org/10.1053/j.gastro.2015.09.007 Ambrosino P, Lupoli R, Di Minno A, Tarantino L, Spadarella G, Tarantino P, et al. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: a systematic review and meta-analysis. Int J Cardiol 2016;221:746–54. https://doi.org/10.1016/j.ijcard.2016.07.118 Villani R, Di Cosimo F, Romano AD, Sangineto M, Serviddio G. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Sci Rep 2021;11:13944. https://doi.org/10.1038/s41598-021-93391-2 Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One 2016;11:e0163644. https://doi.org/10.1371/journal.pone.0163644 Doyle MA, Galanakis C, Mulvihill E, Crawley A, Cooper CL. Hepatitis C direct acting antivirals and ribavirin modify lipid but not glucose parameters. Cells 2019;8:252. https://doi.org/10.3390/cells8030252 Goñi Esarte S, Juanbeltz R, Zozaya JM, Úriz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterol Hepatol 2020;43:248–55. https://doi.org/10.1016/j.gastrohep.2019.10.008 Gitto S, Cicero AFG, Loggi E, Giovannini M, Conti F, Grandini E, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol 2018;17:64–75. https://doi.org/10.5604/01.3001.0010.7538 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7377090","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":508056225,"identity":"78ac601b-a5ab-4f5a-9bf1-b7b606dccfcd","order_by":0,"name":"Haythem Yacoub","email":"","orcid":"","institution":"La Rabta hospital","correspondingAuthor":false,"prefix":"","firstName":"Haythem","middleName":"","lastName":"Yacoub","suffix":""},{"id":508056226,"identity":"4200b220-5f23-4369-b122-b9889edd792d","order_by":1,"name":"Salma Merhaben","email":"data:image/png;base64,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","orcid":"","institution":"La Rabta hospital","correspondingAuthor":true,"prefix":"","firstName":"Salma","middleName":"","lastName":"Merhaben","suffix":""},{"id":508056227,"identity":"ad4a3eb8-d6b8-4421-b417-b5dabbb35322","order_by":2,"name":"Dhouha Cherif","email":"","orcid":"","institution":"La Rabta hospital","correspondingAuthor":false,"prefix":"","firstName":"Dhouha","middleName":"","lastName":"Cherif","suffix":""},{"id":508056228,"identity":"6acdb4f4-7c5a-4bf0-96c1-35305ea3e352","order_by":3,"name":"Habiba Debbabi","email":"","orcid":"","institution":"La Rabta hospital","correspondingAuthor":false,"prefix":"","firstName":"Habiba","middleName":"","lastName":"Debbabi","suffix":""},{"id":508056229,"identity":"cf3428e5-07d5-420f-b954-54dc867b0a62","order_by":4,"name":"Hajer Hassine","email":"","orcid":"","institution":"La Rabta hospital","correspondingAuthor":false,"prefix":"","firstName":"Hajer","middleName":"","lastName":"Hassine","suffix":""},{"id":508056230,"identity":"1dc7fdbe-ba7e-49bb-a240-9d6db2fc584d","order_by":5,"name":"Héla Kchir","email":"","orcid":"","institution":"La Rabta hospital","correspondingAuthor":false,"prefix":"","firstName":"Héla","middleName":"","lastName":"Kchir","suffix":""},{"id":508056231,"identity":"b879e3d3-8032-472e-8310-053ae90076f9","order_by":6,"name":"Nadia Maamouri","email":"","orcid":"","institution":"La Rabta hospital","correspondingAuthor":false,"prefix":"","firstName":"Nadia","middleName":"","lastName":"Maamouri","suffix":""}],"badges":[],"createdAt":"2025-08-14 22:38:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7377090/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7377090/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":91814889,"identity":"8f1812e8-237e-4647-b4dd-cbe257a98be2","added_by":"auto","created_at":"2025-09-22 06:17:50","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1433800,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7377090/v1/4af25ade-63e5-4b1c-832e-6eb34a2cc251.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Metabolic Effects of Direct-Acting Antiviral Therapy in Chronic Hepatitis C: A Focus on Glucose and Lipid Profiles","fulltext":[{"header":"Introduction","content":"\u003cp\u003eHepatitis C virus (HCV) infection remains a significant global public health challenge, affecting approximately 3% of the world\u0026rsquo;s population according to the World Health Organization (WHO)(1). Chronic hepatitis C (CHC) is not only a leading cause of severe hepatic complications, including cirrhosis and hepatocellular carcinoma, but is also increasingly recognized for its association with systemic metabolic disturbances. These include insulin resistance, type 2 diabetes mellitus, and dyslipidemia, all of which contribute to an elevated risk of cardiovascular disease and complicate the clinical management of affected individuals. Interestingly, HCV infection is paradoxically associated with reduced levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, resulting in a distinctive lipid profile whose underlying mechanisms and clinical implications remain incompletely understood.\u003c/p\u003e\n\u003cp\u003eThe advent of second-generation direct-acting antiviral agents (DAAs) has revolutionized the treatment of CHC, offering high rates of sustained virological response (SVR) with minimal side effects. While the primary goal of DAA therapy is to halt liver disease progression and reduce the risk of complications, growing evidence suggests that viral clearance may also influence metabolic parameters, including lipid and glycemic profiles. However, the impact of HCV eradication on lipid and glycemic metabolism remains controversial, with studies reporting conflicting results regarding changes in glucose, triglycerides, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels post-treatment.\u003c/p\u003e\n\u003cp\u003eThis study aims to evaluate changes in lipid and glycemic profiles before and after DAA treatment, focusing on the impact of viral eradication on glucose, triglyceride, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBy addressing these questions, this research seeks to contribute to a more comprehensive understanding of the systemic effects of HCV infection and its treatment, ultimately improving patient care and outcomes.\u003c/p\u003e"},{"header":"Patients and data collection","content":"\u003cp\u003eWe performed a single-center, retrospective, observational study with longitudinal follow-up, conducted in the gastroenterology department at La Rabta Hospital in Tunis.\u003c/p\u003e\n\u003cp\u003eWe included all consecutive patients hospitalized between January 2016 and December 2022.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInclusion criteria\u003c/strong\u003e wereall patients aged 18 years or older with chronic hepatitis C who were followed during the specified period, were DAA-naïve, received DAA therapy, and achieved SVR at both 12 and 48 weeks after the end of treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eExclusion criteria\u003c/strong\u003e were:\u003c/p\u003e\n\u003cul type=\"disc\"\u003e\n \u003cli\u003ePatients withdecompensatedcirrhosis.\u003c/li\u003e\n \u003cli\u003eHepatocellular carcinoma (HCC) at the time of diagnosis or during the 12 months following treatment.\u003c/li\u003e\n \u003cli\u003eCo-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBV).\u003c/li\u003e\n \u003cli\u003eLiver transplant recipients.\u003c/li\u003e\n \u003cli\u003eUse of lipid-lowering therapy.\u003c/li\u003e\n \u003cli\u003eFamilial forms of dyslipidemia.\u003c/li\u003e\n \u003cli\u003ePregnancy\u003c/li\u003e\n \u003cli\u003eIncompletemedical records.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eClinical and demographic data were collected from patients' electronicmedical records. A detailed form was completed, and the variables analyzed included: age, sex, lifestyle habits, and medical history.\u003c/p\u003e\n\u003cp\u003eBiological parameters before the initiation of DAA therapy and after HCV eradication were recorded. For each patient, the degree of fibrosis before starting antiviral treatment was assessed.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment Regimen\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll patients were treated in accordance with the guidelines established by the European Association for the Study of the Liver (EASL) panel. The following treatment regimens were administered: sofosbuvir (SOF) combined with ribavirin (RBV) (SOF/RBV), and sofosbuvir (SOF) combined with ledipasvir (SOF/LDV).\u003c/p\u003e\n\u003cp\u003eSerum HCV RNA levels were measured at multiple time points: before the initiation of therapy and at 12 and 48 weeks after the end of therapy. Sustained virological response was defined as undetectable HCV RNA 12 weeks after the completion of treatment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll the Statistical analysis were carried through Statisti-cal Package for the Social Sciences (SPSS) version 22,0 IBM SPSS Inc.; Chicago, IL, USA).Categorical variables were summarized as frequencies and percentages. Continuous variables were expressed as means with standard deviation (SD) or medians with interquartile range (IQR), depending on the distribution of the data. Group comparisons were performed using the t-test for normally distributed data or the Mann-Whitney test for non-normally distributed continuous variables, as appropriate.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWe then investigated the factors associated with changes in fasting blood glucose and lipid-related markers following HCV therapy with direct-acting antivirals (DAAs). A 10% variation threshold was applied uniformly across all parameters. Based on this threshold, two groups were compared: one exhibiting a \u0026gt;10% variation and one without significant variation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eA p-value \u0026lt; 0.05 and a 95% CI not including 1 were considered statistically significant for all analyses.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eBaseline Characteristics\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDuring the study period, 74 patients were initially screened for inclusion in the study. All of them initiated direct-acting antiviral (DAA) treatment. Of these, 49 patients (4 males and 45 females)met the inclusion criteria and were included in the final analysis.The mean age was 60.8\u0026plusmn;11.8 years. Twenty-five (51%) had a history of hypertension, and five (10%) were diabetic, including two (4%) requiring insulin therapy. Only one patient (2%) had hypertriglyceridemia managed with dietary modifications.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eHepatic risk factors were identified in 36 out of 49 patients (73%), including prior blood transfusion (10 patients, 20%), dental procedures (25 patients, 51%), tattoos (7 patients, 14%), scarifications (22 patients, 45%), and intravenous drug use (2 patients, 4%). The baseline demographics, clinical and biological characteristics of patients are summarized in Tables 1 and 2.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eNo patients tested positive for HBs antigen. Five patients (10%) had positive anti-HBc antibodies with negative HBV PCR, and all of them had protective levels of anti-HBs antibodies (\u0026gt;10 IU/mL). HIV serology was negative in all cases.\u003c/p\u003e\n\u003cp\u003eGenotype 1b was the most prevalent, accounting for 81.6% of cases.Themean virological load was of 3077971,3 UI/L.\u003c/p\u003e\n\u003cp\u003eLiver fibrosis assessment was performed using liver biopsy in 12 patients (24%), primarily for etiological diagnostic clarification. The remaining patients underwent non-invasive fibrosis evaluation via transient elastography (FibroScan, 12 patients, 24%) or FibroTest(25 patients, 51%).\u003c/p\u003e\n\u003cp\u003eOf the 49 patients included in the study, 44 (90%) exhibited significant fibrosis (stage F2 or higher), and 35 (71%) had advanced fibrosis (stage F3 or higher).\u003c/p\u003e\n\u003cp\u003eThirteen patients (27%) exhibited endoscopic signs of portal hypertension.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eCryoglobulinemia was positive in 10 patients (20%). The characteristics of viral hepatitis C infection in our patients were summarized in table 3.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAmong the patients, 37 (75.5%) were treatment-na\u0026iuml;ve, while 12 (24.5%) had prior treatment experience with pegylated interferon.\u003c/p\u003e\n\u003cp\u003eAll patients received hepatitis C virus (HCV) eradication therapy in accordance with the national Tunisian consensus guidelines in effect at the time, prior to the introduction of pangenotypic regimens. Of these, 42 patients (86%) were treated with sofosbuvir and ledipasvir, while 7 patients (14%) received a combination of sofosbuvir and ribavirin(genotype 2 and 3). Treatment duration was 12 weeks in 24 patients (49%) and 24 weeks in 25 patients (51%). Adherence to therapy was excellent in 48 out of 49 patients (98%), with good overall tolerability. Minor adverse effects were reported by 2 patients (4%): one (2%) experienced headache, and another (2%) reported asthenia.\u003c/p\u003e\n\u003cp\u003eThe HCV eradication rate was outstanding, with undetectable HCV PCR at both 12 and 48 weeks post-treatment in 100% of cases. Treatment outcomes were summarized in table 4.\u003c/p\u003e\n\u003cp\u003eWe compared fasting lipid and glucose profiles before treatment and during the first year following the completion of direct-acting antiviral (DAA) therapy.\u003c/p\u003e\n\u003ch3\u003eEvolution of Fasting Blood Glucose and Lipid Profile Before and After HCV Antiviral Therapy (Table 5)\u003c/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003emean fasting blood glucose level\u003c/strong\u003e decreased from \u003cstrong\u003e6.1 mmol/L\u003c/strong\u003e (range: 4.27\u0026ndash;14 mmol/L; SD = 2.1) before treatment to \u003cstrong\u003e5.8 mmol/L\u003c/strong\u003e (range: 4.0\u0026ndash;13.5 mmol/L; SD = 1.86) after treatment, with a \u003cstrong\u003estatistically significant difference\u003c/strong\u003e (\u003cstrong\u003ep = 0.048\u003c/strong\u003e).\u003c/p\u003e\n\u003cp\u003eThe \u003cstrong\u003emean total cholesterol level\u003c/strong\u003e increased from \u003cstrong\u003e3.8 mmol/L\u003c/strong\u003e (range: 2.16\u0026ndash;5.58 mmol/L; SD = 0.87) to \u003cstrong\u003e4.1 mmol/L\u003c/strong\u003e (range: 1.4\u0026ndash;6.1 mmol/L; SD = 0.86), also showing a \u003cstrong\u003estatistically significant difference\u003c/strong\u003e (\u003cstrong\u003ep = 0.015\u003c/strong\u003e).\u003c/p\u003e\n\u003cp\u003eThe \u003cstrong\u003emean triglyceride level\u003c/strong\u003e showed a slight decrease from \u003cstrong\u003e1.26 mmol/L\u003c/strong\u003e (range: 0.5\u0026ndash;3.1 mmol/L; SD = 0.6) to \u003cstrong\u003e1.19 mmol/L\u003c/strong\u003e (range: 0.7\u0026ndash;3.62 mmol/L; SD = 0.64), but this change was \u003cstrong\u003enot statistically significant\u003c/strong\u003e(\u003cstrong\u003ep =0.318\u003c/strong\u003e).\u003c/p\u003e\n\u003cp\u003eThe \u003cstrong\u003emean HDL-cholesterol level\u003c/strong\u003e increased from \u003cstrong\u003e1.1 mmol/L\u003c/strong\u003e (range: 0.41\u0026ndash;1.91 mmol/L; SD = 0.34) to \u003cstrong\u003e1.28 mmol/L\u003c/strong\u003e (range: 0.8\u0026ndash;1.91 mmol/L; SD = 0.29), with \u003cstrong\u003eno statistically significant difference\u003c/strong\u003e observed (\u003cstrong\u003ep =0.345\u003c/strong\u003e).\u003c/p\u003e\n\u003cp\u003eSimilarly, the \u003cstrong\u003emean LDL-cholesterol level\u003c/strong\u003e rose slightly from \u003cstrong\u003e2.1 mmol/L\u003c/strong\u003e (range: 0.49\u0026ndash;4.06 mmol/L; SD = 0.8) to \u003cstrong\u003e2.28 mmol/L\u003c/strong\u003e (range: 0.4\u0026ndash;4.1 mmol/L; SD = 0.82), with \u003cstrong\u003eno statistically significant change\u003c/strong\u003e(\u003cstrong\u003ep =0.440\u003c/strong\u003e).\u003c/p\u003e\n\u003cp\u003eIn the univariate analysis, a significant association was observed between the \u0026gt;10% variation in fasting blood glucose and a single clinical parameter: the initial viral load (p = 0.031) .However, no significant correlation was found in the multivariate analysis (table 6).\u003c/p\u003e\n\u003cp\u003eNo significant correlation was observed between a \u0026gt;10% variation in triglyceride levels and the variables studied, either in univariate or multivariate analysis.\u003c/p\u003e\n\u003cp\u003eNo significant correlation was observed between a\u0026gt;10% variation in total cholesterol levels and the variables studied, either in univariate or multivariate analysis (table 7).\u003c/p\u003e\n\u003cp\u003eIn the univariate analysis, a significant association was observed between the \u0026gt;10% variation in HDL cholesterol and only one clinical parameter: initial disturbance in liver function tests (p = 0.02). However, no significant correlation was found in the multivariate analysis.\u003c/p\u003e\n\u003cp\u003eNo significant correlation was observed between a \u0026gt;10% variation in LDL-cholesterol levels and the variables studied, either in univariate or multivariate analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1. Baseline Demographics and Clinical Characteristics of Patients\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"627\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eParameter\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal (n = 49)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eN, percentage\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSex , n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eFemale\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003eMale\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e45(92%)\u003c/p\u003e\n \u003cp\u003e4 (8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eMale-to-Female Ratio\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1:11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eMean Age (years) ,mean ( SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e60.8(11.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eMean Weight (kg) mean, ( SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e70 (13.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eMean BMI (kg/m\u0026sup2;),mean, ( SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e28.2 (4.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eComorbidities\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Hypertension\u003cstrong\u003e\u0026nbsp;n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e25(51%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Diabetes mellitus\u003cstrong\u003e\u0026nbsp;n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5(10%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Insulin-dependent\u003cstrong\u003e\u0026nbsp;n (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2(4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Hypertriglyceridemia (diet-controlled) \u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1(2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Chronic kidney disease (hemodialysis) \u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1(2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Hypothyroidism (on replacement therapy, euthyroid) \u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e4(8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Coronary artery disease\u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2(4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- History of Extrahepatic Malignancies (in remission) (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e2(4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eSmoking and alcohol Use\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Smokers(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e5(10%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Mean Pack-Years\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- AlcoholConsumers(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e1 (2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eHepaticRiskFactors\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e36 (73%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Prior Blood Transfusion(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e10 (20%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Dental Procedures(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e25 (51%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Tattoos(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e7 (14%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e- Scarifications(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e22 (45%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 443px;\"\u003e\n \u003cp\u003e- Intravenous Drug Use(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 185px;\"\u003e\n \u003cp\u003e2 (4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2. Baseline Biological Characteristics of Patients\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"631\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBiologicalParameters\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBaseline (Mean \u0026plusmn; SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- Hemoglobin (g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e12.6 \u0026plusmn; 2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- Platelet Count (cells/mm\u0026sup3;)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e158,659 \u0026plusmn;84913.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- Prothrombin Time (TP, %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e82 \u0026plusmn; 14.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- INR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e1.11 \u0026plusmn; 0.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- Total Bilirubin (\u0026micro;mol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e14.7 \u0026plusmn; 9.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- Albumin (g/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e37.2 \u0026plusmn; 4.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- AST (ASAT, \u0026times; ULN)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e1.9 \u0026plusmn;1.2\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 366px;\"\u003e\n \u003cp\u003e- ALT (ALAT, \u0026times; ULN)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 265px;\"\u003e\n \u003cp\u003e1.4 \u0026plusmn;1.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3. Characteristics of viral hepatitis C infection in our patients\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003cimg src=\"data:image/png;base64,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\" width=\"457\" height=\"567\"\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4. Treatment outcomes of viral hepatitis C in our patients \u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"627\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003eTreatment-Na\u0026iuml;ve Patients(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e37 (76%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003ePreviously Treated with Pegylated IFN(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e12 (25%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHCV Eradication Therapy\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eSofosbuvir + Ledipasvir(%)\u003c/p\u003e\n \u003cp\u003eSofosbuvir + Ribavirin(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e42 (86%)\u003c/p\u003e\n \u003cp\u003e7 (14%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatment Duration\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;12 Weeks(%)\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;24 Weeks(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e24 (49%)\u003c/p\u003e\n \u003cp\u003e25 (51%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTreatmentAdherence\u003c/strong\u003e(%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e48 (98%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAdverse Effects\u003c/strong\u003e(%)\u003c/p\u003e\n \u003cp\u003eHeadache (n, %)\u003c/p\u003e\n \u003cp\u003eAsthenia (n, %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e2 (4%)\u003c/p\u003e\n \u003cp\u003e1 (2%)\u003c/p\u003e\n \u003cp\u003e1 (2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 385px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHCV Eradication Rate (Negative PCR at 12 \u0026amp; 48 Weeks)\u003c/strong\u003e (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 242px;\"\u003e\n \u003cp\u003e49 (100%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5. Changes in Fasting Blood Glucose and Lipid-Related Markers after HCV therapy with DAA\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"621\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 243px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eStudied parameter\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 161px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBaseline (Mean \u0026plusmn; SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 142px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAfter treatment (Mean \u0026plusmn; SD)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 76px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eP value\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 243px;\"\u003e\n \u003cp\u003eFasting Glucose (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 161px;\"\u003e\n \u003cp\u003e6.1 \u0026plusmn; 2.1\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 142px;\"\u003e\n \u003cp\u003e5.8 \u0026plusmn; 1.9\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 76px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.048\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 243px;\"\u003e\n \u003cp\u003eTotal Cholesterol (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 161px;\"\u003e\n \u003cp\u003e3.8 \u0026plusmn; 0.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 142px;\"\u003e\n \u003cp\u003e4.1 \u0026plusmn; 0.9\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 76px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.015\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 243px;\"\u003e\n \u003cp\u003eTriglycerides (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 161px;\"\u003e\n \u003cp\u003e1.2 \u0026plusmn; 0.6\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 142px;\"\u003e\n \u003cp\u003e1.2 \u0026plusmn; 0.6\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 76px;\"\u003e\n \u003cp\u003e0.318\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 243px;\"\u003e\n \u003cp\u003eHDL Cholesterol (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 161px;\"\u003e\n \u003cp\u003e1.1 \u0026plusmn; 0.3\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 142px;\"\u003e\n \u003cp\u003e1.3 \u0026plusmn; 0.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 76px;\"\u003e\n \u003cp\u003e0.345\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 243px;\"\u003e\n \u003cp\u003eLDL Cholesterol (mmol/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 161px;\"\u003e\n \u003cp\u003e2.1 \u0026plusmn; 0.8\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 142px;\"\u003e\n \u003cp\u003e2.28 \u0026plusmn; 0.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 76px;\"\u003e\n \u003cp\u003e0.440\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eTable 6. Factors Associated with\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026Delta;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;Fasting Blood Glucose value after HCV therapy with DAA regimen, Analyzed by Multiple Logistic-regression Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eStudied parameter\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026Delta;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;FBG \u0026gt;10%n(%)/mean \u0026plusmn;SD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026Delta;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;FBG \u0026lt; 10%\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003en(%)/mean \u0026plusmn;SD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003eUnivariate\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003eMultivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003eOR (95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"47\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003eP-Value\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e\u0026nbsp;P-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"48\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e(n=6)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e(n=43)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"23\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003eAge, year\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e62.1\u0026plusmn;14.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e60.5\u0026plusmn;9.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e0.790\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e0.274\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003e1.095\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003eSex,Male(n=4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e0(0%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e4(100%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e0.999\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003e0.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003eBMI \u0026nbsp;(kg/m2 )\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e25.1\u0026plusmn;5.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e28.7\u0026plusmn;4.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e0.238\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e0.178\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003e0.829\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003eHCV-RNA (10\u003csup\u003e6\u003c/sup\u003eUI/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e8.7\u003c/strong\u003e\u003cstrong\u003e\u0026plusmn;1.1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e34\u003c/strong\u003e\u003cstrong\u003e\u0026plusmn;37.7\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.031\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e0.359\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003eAST \u0026gt;ULN\u003c/p\u003e\n \u003cp\u003e(n=20)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e3(15%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e17(85%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e0.683\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e0.308\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003e12.119\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003eALT \u0026gt;ULN\u003c/p\u003e\n \u003cp\u003e(n=31)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e6(19%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e25 (81%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e0.649\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e0.279\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003e0.181\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 130px;\"\u003e\n \u003cp\u003eFibrosis \u0026gt;F2\u003c/p\u003e\n \u003cp\u003e(n=35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 136px;\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 100px;\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e0.309\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 91px;\"\u003e\n \u003cp\u003e0.999\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 73px;\"\u003e\n \u003cp\u003e0.957\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eFBG: Fasting blood glucose\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 7. Factors Associated with\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026Delta;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;cholesterol value after HCV therapy with DAA regimen, Analyzed by Multiple Logistic-regression Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"3\" valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eStudied parameter\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026Delta;cholesterol \u0026gt;10%\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003en(%)/mean \u0026plusmn; SD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026Delta;cholesterol \u0026lt; 10%\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003en(%)/mean \u0026plusmn; SD\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eUnivariate\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003eMultivariate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"3\" valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eOR (95% CI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"47\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eP-Value\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e\u0026nbsp;P-Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"48\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e(n= 17)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e(n=32)\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd height=\"23\" style=\"width: 0px;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eAge, year\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e59.2\u003cstrong\u003e\u0026plusmn;11.0\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e61.9\u003cstrong\u003e\u0026plusmn;12.1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.451\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e0.692\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eSex, Male (n=4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.602\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e0.379\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e3.516\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eBMI \u0026nbsp;(kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e28.4\u0026plusmn;5.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e28.3\u0026plusmn;5.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.984\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e0.643\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.035\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eHCV-RNA (10\u003csup\u003e6\u0026nbsp;\u003c/sup\u003eIU/ml)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e37.0\u003cstrong\u003e\u0026plusmn;\u003c/strong\u003e43.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e29.1\u0026plusmn;32.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.529\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e0.260\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e1.000\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eAST \u0026gt; ULN\u003c/p\u003e\n \u003cp\u003e(n=32)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e11(34,4%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e21 (65,6%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.739\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e0.159\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.522\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eALT \u0026gt; ULN\u003c/p\u003e\n \u003cp\u003e(n=21)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e6 (29%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e15(71%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.756\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e0.212\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e2.373\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003eFibrosis \u0026gt;F2\u003c/p\u003e\n \u003cp\u003e(n=34)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e13 (38,2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e21(61,8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e0.739\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 107px;\"\u003e\n \u003cp\u003e0.305\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 102px;\"\u003e\n \u003cp\u003e2.576\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 0px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e"},{"header":"Discussion","content":"\u003cp\u003eHCV infection exerts significant metabolic effects beyond its primary hepatic manifestations and is consistently associated with alterations in lipid metabolism, including lower serum cholesterol and triglyceride levels (2-4). Several studies have also demonstrated reductions in both HDL-C and LDL-C levels (5). These changes can be partly attributed to the HCV core protein, which downregulates the expression of peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor regulating genes involved in fatty acid oxidation. Reduced hepatic levels of PPAR-α mRNA have been observed in HCV-infected patients (6,7). Additionally, the HCV core protein is thought to inhibit microsomal triglyceride transfer protein (MTP) activity, an enzyme essential for the assembly and secretion of very low-density lipoproteins (VLDL), potentially leading to impaired VLDL synthesis and triglyceride accumulation (8).\u003c/p\u003e\n\u003cp\u003eDespite this seemingly favorable lipid profile, HCV infection has been associated with an increased risk of atherosclerosis and cardiovascular events (9). Indeed, patients with HCV infection have a higher risk of major cardiovascular events compared to uninfected controls, independent of liver disease severity or traditional cardiovascular risk factors (10,11).\u003c/p\u003e\n\u003cp\u003eIn addition to its impact on lipid profiles, HCV has also been implicated in impaired glucose metabolism, with numerous studies reporting an increased prevalence of insulin resistance (IR) and type 2 diabetes mellitus (DM) in HCV-infected individuals. These metabolic disturbances may result from direct viral interference with insulin signaling as well as indirect mechanisms involving hepatic steatosis and chronic inflammation (5).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eWith the advent of direct-acting antiviral (DAA) agents, the long-standing goal of HCV eradication has been achieved through highly effective and well-tolerated therapies. However, questions have arisen regarding their effects on lipid and glucose metabolism. When comparing fasting lipid and glucose profiles before treatment and during the first year following the completion of direct-acting antiviral (DAA) therapy,findings across various studies may be inconsistent or even contradictory.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvolution of lipids profile:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn our study, total cholesterol levels showed a significant increase after treatment, while triglyceride levels decreased slightly; however, this change was not statistically significant. Similarly, both HDL and LDL cholesterol levels exhibited modest increases, though these changes did not reach statistical significance.\u003c/p\u003e\n\u003cp\u003eA meta-analysis published by Villani et al. in 2021 synthesized data from fourteen observational studies to assess the extent of serum lipid profile changes during DAA therapy (12). The findings indicated that DAA treatment induces a mild but statistically significant increase in serum cholesterol levels, regardless of the antiviral regimen used, consistent with the results of our study. This increase appears to be primarily driven by an early rise in LDL cholesterol observed shortly after treatment initiation. On average, total cholesterol levels increased by approximately 19 mg/dL at SVR12 and 20 mg/dL at SVR24.\u003c/p\u003e\n\u003cp\u003eThe same meta-analysis revealed a significant increase in HDL-cholesterol levels both during and after direct-acting antiviral (DAA) treatment. On treatment, HDL levels increased by an average of 2.62 to 4 mg/dL, and after treatment completion, this increase ranged from 3.17 to 4.34 mg/dL. These changes were statistically significant at multiple time points, including 4 and 8 weeks, as well as at SVR12 and SVR24.\u003c/p\u003e\n\u003cp\u003eThese results could be partly explained by the suggestion of Hashimoto et al., who proposed that that the rapid suppression of HCV core proteins induced by direct-acting antiviral (DAA) therapy may disrupt host lipid metabolism, leading to a reduction in lipid droplet production in HCV-infected liver cells and a significant rebound in circulating LDL levels(13).\u003c/p\u003e\n\u003cp\u003eDespite these findings, heterogeneity across studies was noted, indicating variability in the response, particularly with different antiviral regimens and different virus genotypes.\u003c/p\u003e\n\u003cp\u003eIn fact, Doyle et al. reported that lipid changes during treatment appeared to be influenced by ribavirin exposure, suggesting a direct impact of this drug on lipid homeostasis. In particular, non-cirrhotic patients receiving ribavirin showed reductions in total cholesterol, LDL-C, and apoB levels at Weeks 4 and 12 post treatment(14).\u003c/p\u003e\n\u003cp\u003eRegarding triglycerides, the pooled data from ten studies out of fourteen from the same meta-analysis showed no significant changes in triglyceride levels during or after DAA therapy. At 4 weeks, there was a minor decrease, and at SVR12, there was a small increase, but neither change reached statistical significance. This suggests that, unlike HDL-cholesterol, triglyceride levels are not notably affected by antiviral therapy, regardless of the timing after treatment or the specific antiviral regimen used(12).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvolution of glucose profile:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn our study,we found a significant reduction in fasting blood glucose levels following HCV antiviral therapy. Our findings are consistent with those of a Spanish study published in 2019, in which median serum glucose levels decreased from 95 (88–105) to 94 (86–103) mg/dL (p = 0.008).(15)\u003c/p\u003e\n\u003cp\u003eAn Italian study conducted by Gitto et al. revealed that the mean glycemia values remained unchanged, whereas mean insulin levels and HOMA-IR significantly decreased (from 16.5 ± 7.3 to 11.6 ± 5.8, p \u0026lt; 0.001, and from 3.8 ± 1.9 to 2.7 ± 1.5, p \u0026lt; 0.001, respectively)(16).\u003c/p\u003e\n\u003cp\u003eIn contrast, Doule et al. reported no consistent changes in glucose homeostasis during treatment or after achieving SVR. Specifically, HOMA-IR values did not improve from baseline at any point during or following DAA therapy (14).\u003c/p\u003e\n\u003cp\u003eThe majority of studies suggest an improvement in glucose metabolism accompanied by worsening of the lipid profile, prompting some authorsto raise concerns regarding the overall cardiovascular balance in patients with CHC (16). Although these changes may be statistically significant, their clinical relevance in terms of cardiovascular risk remains questionable. Therefore, future research should aim to evaluate the true cardiovascular impact of these metabolic changes in high-risk CHC patients and to determine any potential clinical benefits.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eThis study has several limitations.\u003c/strong\u003e First, the relatively small number of patients included. Second, the retrospective design inherently carries potential biases. Additionally, we were unable to collect detailed information on behavioral factors known to influence the natural history of CHC, such as alcohol consumption, dietary habits, and physical activity. Finally, body weight and body mass index (BMI) were not recorded after virus clearance, limiting our ability to assess potential metabolic changes post-treatment.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThis study highlights the systemic impact of HCV beyond liver disease, particularly its influence on metabolic parameters. Following successful treatment with DAAs, we observed a significant decrease in fasting blood glucose levels and an increase in total cholesterol. Although changes in HDL, LDL, and triglycerides were not statistically significant, the trends align with previous studies suggesting a metabolic shift post-HCV eradication. These findings reinforce the importance of monitoring metabolic parameters after viral clearance, especially in patients with cardiovascular risk factors. Further prospective studies with larger cohorts are needed to better understand the long-term clinical implications of these changes.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eDeclarations Ethics approval and consent to participate\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was performed according to the Declaration of Helsinki, following the guidelines for good clinical practice. \u0026ldquo;La Rabtahospital ethics committee\u0026rdquo; approved the study protocol. All methods were carried out in accordance with relevant guidelines and regulations. Informed consent to participate in the study was obtained from participants.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u003c/strong\u003e Not applicable.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e: The authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eH.Y:\u003c/strong\u003e concept, design, definition of intellectual content, literature search, manuscript preparation, manuscript editing, manuscript review.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eS.M:\u003c/strong\u003e concept, design, definition of intellectual content, manuscript preparation, manuscript review.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eD.C:\u003c/strong\u003e Definition of intellectual content, manuscript preparation, design, manuscript review.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eH.D:\u003c/strong\u003e Definition of intellectual content, design.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eH.H:\u003c/strong\u003e Definition of intellectual content, manuscript preparation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eH.K:\u003c/strong\u003e Definition of intellectual content, manuscript preparation.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eN.M:\u003c/strong\u003e Definition of intellectual\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMohdHanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333\u0026ndash;42. https://doi.org/10.1002/hep.26141\u003c/li\u003e\n\u003cli\u003eFabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997;261:159\u0026ndash;65. https://doi.org/10.1016/S0009-8981(97)06483-8\u003c/li\u003e\n\u003cli\u003eSiagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006;13:56\u0026ndash;61. https://doi.org/10.1111/j.1365-2893.2005.00650.x\u003c/li\u003e\n\u003cli\u003eMarzouk D, Sass J, Bakr I, El Hosseiny M, Abdel-Hamid M, Rekacewicz C, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007;56:1105\u0026ndash;10. https://doi.org/10.1136/gut.2006.099630\u003c/li\u003e\n\u003cli\u003eDai C, Yeh M, Huang C, Hou C, Hsieh M, Huang J, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2015;30:879\u0026ndash;84. https://doi.org/10.1111/jgh.12856\u003c/li\u003e\n\u003cli\u003eDe Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, et al. Peroxisome proliferator-activated receptor-\u0026alpha; and -\u0026gamma; mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 2006;23:107\u0026ndash;14. https://doi.org/10.1111/j.1365-2036.2006.02738.x\u003c/li\u003e\n\u003cli\u003eDharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, et al. Impaired expression of the peroxisome proliferator\u0026ndash;activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005;128:334\u0026ndash;42. https://doi.org/10.1053/j.gastro.2004.11.004\u003c/li\u003e\n\u003cli\u003ePerlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chr\u0026eacute;tien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002;16:185\u0026ndash;94. https://doi.org/10.1096/fj.01-0468com\u003c/li\u003e\n\u003cli\u003eAmpuero J, Romero-G\u0026oacute;mez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol 2015;7:2214\u0026ndash;9. https://doi.org/10.4254/wjh.v7.i19.2214\u003c/li\u003e\n\u003cli\u003ePetta S, Maida M, Macaluso FS, Barbara M, Licata A, Crax\u0026igrave; A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 2016;150:145\u0026ndash;55.e4. https://doi.org/10.1053/j.gastro.2015.09.007\u003c/li\u003e\n\u003cli\u003eAmbrosino P, Lupoli R, Di Minno A, Tarantino L, Spadarella G, Tarantino P, et al. The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: a systematic review and meta-analysis. Int J Cardiol 2016;221:746\u0026ndash;54. https://doi.org/10.1016/j.ijcard.2016.07.118\u003c/li\u003e\n\u003cli\u003eVillani R, Di Cosimo F, Romano AD, Sangineto M, Serviddio G. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Sci Rep 2021;11:13944. https://doi.org/10.1038/s41598-021-93391-2\u003c/li\u003e\n\u003cli\u003eHashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One 2016;11:e0163644. https://doi.org/10.1371/journal.pone.0163644\u003c/li\u003e\n\u003cli\u003eDoyle MA, Galanakis C, Mulvihill E, Crawley A, Cooper CL. Hepatitis C direct acting antivirals and ribavirin modify lipid but not glucose parameters. Cells 2019;8:252. https://doi.org/10.3390/cells8030252\u003c/li\u003e\n\u003cli\u003eGo\u0026ntilde;i Esarte S, Juanbeltz R, Zozaya JM, \u0026Uacute;riz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterol Hepatol 2020;43:248\u0026ndash;55. https://doi.org/10.1016/j.gastrohep.2019.10.008\u003c/li\u003e\n\u003cli\u003eGitto S, Cicero AFG, Loggi E, Giovannini M, Conti F, Grandini E, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol 2018;17:64\u0026ndash;75. https://doi.org/10.5604/01.3001.0010.7538\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-7377090/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7377090/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eHepatitis C virus (HCV) infection is a leading global cause of chronic liver disease and is increasingly recognized for its extrahepatic metabolic consequences, particularly in lipid and glucose homeostasis. The introduction of direct-acting antiviral agents (DAAs) has revolutionized HCV therapy, enabling high sustained virological response (SVR) rates. However, the metabolic impact of viral eradication remains incompletely understood. This study aimed to evaluate changes in fasting lipid and glycemic parameters following successful DAA therapy.\u003c/p\u003e\n\u003cp\u003eA single-center, retrospective observational study was conducted at La Rabta Hospital (Tunis), including 49 consecutive patients with chronic hepatitis C who received DAA therapy between 2016 and 2022 and achieved SVR at both 12 and 48 weeks post-treatment. Patients with confounding metabolic or hepatic comorbidities were excluded. Fasting glucose, total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol levels were compared before and after antiviral therapy.\u003c/p\u003e\n\u003cp\u003ePost-treatment, a statistically significant reduction in mean fasting glucose was observed (6.1 ± 2.1 to 5.8 ± 1.9 mmol/L; \u003cem\u003ep\u003c/em\u003e = 0.048), alongside a significant increase in total cholesterol (3.8 ± 0.8 to 4.1 ± 0.9 mmol/L; \u003cem\u003ep\u003c/em\u003e = 0.015). Changes in triglycerides, HDL-C, and LDL-C were not statistically significant.\u003c/p\u003e\n\u003cp\u003eThese findings suggest that HCV eradication via DAA therapy may improve glycemic control and an increase total cholesterol. Routine metabolic surveillance post-SVR is advisable, particularly in patients with elevated cardiovascular risk. Further prospective studies are warranted to elucidate the long-term clinical implications.\u003c/p\u003e","manuscriptTitle":"Metabolic Effects of Direct-Acting Antiviral Therapy in Chronic Hepatitis C: A Focus on Glucose and Lipid Profiles","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-02 15:40:39","doi":"10.21203/rs.3.rs-7377090/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"3cf61cc5-b9d4-4aaa-9a40-452e2c5412c8","owner":[],"postedDate":"September 2nd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-09-22T05:53:43+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-02 15:40:39","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7377090","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7377090","identity":"rs-7377090","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}